Endogenous Opioid Mechanisms for Rejection Sensitivity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02189785|
Recruitment Status : Recruiting
First Posted : July 15, 2014
Last Update Posted : January 2, 2018
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||96 participants|
|Official Title:||Endogenous Opioid Mechanisms for Rejection Sensitivity|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
- Mu-opioid binding potential [ Time Frame: within 30 days of informed consent ]This study will measure levels of radiotracer (carbon-11-labeled carfentanil) binding to the mu-opioid receptor in the brain using positron-emission tomography (PET). Primary regions of interest include: the amygdala, anterior insular cortex, anterior cingulate cortex, nucleus accumbens, and thalamus. All structures will be examined bilaterally. Differences in binding potential (Bmax/Kd) for the radiotracer will be compared across different experimental conditions (e.g., neutral, positive, negative social feedback).
- fMRI blood-oxygen-level-dependent (BOLD) response [ Time Frame: within 30 days of informed consent ]This study will measure brain activation in response to social feedback and monetary reward. Primary regions of interest include: the amygdala, anterior insular cortex, and the nucleus accumbens. All structures will be examined bilaterally. Arbitrary units for fMRI BOLD are used to compare activation during one condition (e.g., neutral, baseline) vs. another condition (e.g., positive social feedback, monetary reward).
- Plasma cortisol [ Time Frame: within 30 days of informed consent ]This study will collect blood every 10 minutes during PET to measure changes in levels of plasma cortisol. Units are ug/dL.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189785
|Contact: Kristen Villalobos, BS||(734) firstname.lastname@example.org|
|United States, Michigan|
|University of Michigan||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Kristen Villalobos, BS 734-232-0433 email@example.com|
|Sub-Investigator: Stephan F Taylor, M.D.|
|Principal Investigator:||David T Hsu, Ph.D.||Stony Brook University|